CVRx Inc (CVRX) - Total Liabilities
Based on the latest financial reports, CVRx Inc (CVRX) has total liabilities worth $70.62 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is CVRx Inc growing its equity to track the company's year-over-year net asset growth rate.
CVRx Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how CVRx Inc's total liabilities have evolved over time, based on quarterly financial data.
CVRx Inc Competitors by Total Liabilities
The table below lists competitors of CVRx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FarmStory Co. Ltd
KQ:027710
|
Korea | ₩618.55 Billion |
|
AURRIGO INT.PLCLS-002
F:CI0
|
Germany | €5.68 Million |
|
Luo Lih Fen Holding Co Ltd
TW:6666
|
Taiwan | NT$445.81 Million |
|
Mirae Asset Daewoo Co Ltd
KO:006805
|
Korea | ₩136.81 Trillion |
|
Xin Chio Global Co Ltd
TWO:3171
|
Taiwan | NT$668.54 Million |
|
Lacroix Group SA
PA:LACR
|
France | €341.60 Million |
|
Maat Pharma SA
PA:MAAT
|
France | €40.58 Million |
|
Pmv Pharmaceuticals Inc
NASDAQ:PMVP
|
USA | $11.85 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down CVRx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CVRx Inc (CVRX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CVRx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CVRx Inc (2019–2025)
The table below shows the annual total liabilities of CVRx Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $65.47 Million | +4.99% |
| 2024-12-31 | $62.36 Million | +58.75% |
| 2023-12-31 | $39.28 Million | +149.30% |
| 2022-12-31 | $15.76 Million | +139.14% |
| 2021-12-31 | $6.59 Million | -98.16% |
| 2020-12-31 | $358.01 Million | +16.18% |
| 2019-12-31 | $308.15 Million | -- |
About CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased … Read more